Publications & Reports

CXCL-10, IL-12 and IL-21 are not immunological predictors of HBeAg seroconversion in HIV-1-HBV coinfection following HBV-active antiretroviral therapy (ART).

Giarda P, Avihingsanon A, Sasadeusz J, Audsley J, Marks P, Matthews G, Ruxrungtham K, Lewin SR, Crane M
Department of Translational Medicine, Universita degli Studi del Piemonte Orientale "A.Avogadro", Novara, Italy.

Abstract

BACKGROUND: Interferon stimulated chemokine CXCL-10, interleukin (IL)-12 (p70) and IL-21 have been associated with HBsAg and HBeAg loss following treatment of HBV mono-infection. The aim of this study was to determine whether these factors were also associated with HBsAg and HBeAg loss in HIV-HBV co-infected patients following HBV-active combination antiretroviral therapy (ART). METHODS: HIV-HBV co-infected patients with HBeAg seroconversion (n=12, seroconverters, SC) were compared to patients who did not seroconvert (n=13, non-seroconverters, NSC). CXCL-10, IL-12 and IL-21 (Luminex bead array) were measured in plasma prior to initiation of HBV-active cART (baseline), at the time of seroconversion (T0) and at the closest timepoint before (T-1) and after (T+1) seroconversion. RESULTS: Levels of CXCL-10 declined significantly in all patients following HBV-active ART (p<0.05 for both SC and NSC; Kruskall-Wallis, Dunn’s post test). There was no difference between SC and NSC in the level of CXCL-10, IL-12 and IL-21 at any time point. CONCLUSIONS: We found no evidence that CXCL-10, IL-12 or IL-21 were associated with HBeAg seroconversion following HBV-active ART. Other immunological determinants should be explored in this setting.

Publication

  • Journal: Antiviral therapy
  • Published: 16/01/2014
  • Volume: 19
  • Issue: 4
  • Pagination: 429-433

Health Issue